Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction
Date:8/20/2008

CHENGDU, China, Aug. 20 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc. (OTC Bulletin Board: TYNP, TYNPE), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that the Company's stock symbol had been inadvertently changed to OTC BB: TYNPE due to the electronic eligibility system error.

The error is being corrected immediately and the Company expects the stock symbol to trade under the symbol OTC BB: TYNP on Thursday, August 21, 2008.

Tianyin Pharmaceutical Co., Inc. is a fully-reporting company and the Company's fiscal year ends on June 30. The Company will file its 10K for FY2008 on a timely manner, which is due on September 30. The Company has been compliant is all its fillings.

"This symbol error was very unfortunate and we do wish to assure our shareholders that there is absolutely no problem with Tianyin Pharmaceutical," said Dr. Jiang, Chairman and CEO of Tianyin Pharmaceutical Co., Inc. ''We will announce earnings results for fiscal year 2008 that ended June 30, 2008 before the reporting deadline of September 30, 2008. Additionally, we would like to reiterate that the Company expects to exceed its fiscal year 2008 make good of $5.6 million in net income or fully diluted EPS of $0.16 per share.''

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 34 modernized TCMs in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 51 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,187 employees. Tianyin achieved revenue of $20.4 million and net income of $3.95 million in FY2007 ending June 30, 2007. For more information about Tianyin Pharmaceuticals, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

Contacts:

For the Company:

Allen Tang, Ph.D., MBA, Assistant to the CEO

Tel: +86-158-2122-5642 (China)

Email: Allen.y.tang@gmail.com

Investors:

HC International, Inc.

Alan Sheinwald

Tel: 914-669-0222 (US)

Email: Alan.Sheinwald@hcinternational.net


'/>"/>
SOURCE Tianyin Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
2. Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time
3. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
4. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
5. Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors
6. Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
8. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 2016 , ... Spring Fertility , the only fertility ... egg freezing, today announced the grand opening of its first location in San ... Fertility offers both fertility preservation (egg, sperm, embryo, and testicular and ovarian tissue ...
(Date:5/5/2016)... Francisco, CA (PRWEB) , ... ... ... intensive lectures and hands-on exercises, the Wharton Seminars for Business Journalists ... a better understanding of key business and economic issues.  This one-day program ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... announces McLaughlin & Smoak Benefits as the latest addition to its family of ... a dedicated team of compliance, wellness, human resources, and health care consumerism specialists. ...
(Date:5/5/2016)... ... May 05, 2016 , ... Every year 220 Mississippi kids ... of these children. The wishes provide hope and motivation through positive experiences ... Make-A-Wish Mississippi, Brent Wilson said, “In 2016, the organization will grant 50% of ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... commencement of a master charity program created to assist the people of their ... working closely with nonprofit organizations and community leaders. Their hope is to bring ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 2016 Yissum Research Development ... today that it had signed an exclusive world-wide licensing ... of novel protein degradation and immunomodulatory drugs for cancer ... drug candidates representing first-in-class therapy for hematologic and solid ... The novel technology was developed by ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Myeloid Leukemia ...  report to their offering.       ... Acute Myeloid Leukemia Market and Competitive Landscape ... Myeloid Leukemia pipeline products, Acute Myeloid Leukemia ...
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
Breaking Medicine Technology: